

MEETING SUMMARY OF APPROVED RECOMMENDATIONS

Recommendations made and approved at the April 6, 2018 DCF PMAC meeting. **Your comments, suggestions, etc. are WELCOME.**

DRUG CLASS REVIEW: Non-stimulant ADHD medications.

- A change in max dosing was recommended and approved:
 - i. Atomoxetine: 1.4mg/kg up to 70kg, 100mg if over 70kg.
 - ii. Bupropion: 300mg (rationale for dose change to be presented at next PMAC meeting).
- Recommended and approved that a new dosage form of a currently approved medication does not require a separate review and approval process to be placed in the Protocol as an approved medication.

OTHER

- A comprehensive tool regarding stimulant medications with generic alternatives and other detailed information will be distributed via email to all PMAC members and will be used as a reference tool by CMCU staff.

DCF Psychotropic Medication Advisory Committee
Meeting Minutes
April 6, 2018, 1:00 PM

Present: See attendance sheet

1. Dr. Nikolov called the meeting to order at 1:07M.
2. The date/time of the next meeting is scheduled for May 4, 2018 from 1pm – 2:30pm at Albert J. Solnit Children’s Center 915 River Rd Middletown CT, A Building, Conference Rm A.
3. The minutes of the March 2018 meeting were reviewed and approved.
4. Announcements: Ketamine clinic: Lori Calabrese was contacted: noted all dosing is weight based. Patients typically received 6 infusions over 2-3 weeks although some may require a “booster”. Response time is measured in months to years. Usual practice parameters require the patient to be at least 14yrs old. This procedure is not covered by insurance. Treatment follows an initial consultation/work up.
Dr. Nikolov will attempt to get an M.D. from Yale to give a presentation on this subject as they have a program.

Note: recruitment is underway for CMCU positions: Psychiatrist, APRN, Hospitalist.

5. Medication Therapeutic Class Review: Non-stimulant ADHD medications:
 - A change in max dosing was recommended discussed in detail and approved: No other changes recommended.
 - i. Atomoxetine: 1.4mg/kg up to 70kg, 100mg if over 70kg.
 - ii. Bupropion: 300mg (rationale for dose change to be presented at next PMAC meeting).

There was a discussion regarding the dosing of Focalin IR vs Focalin ER. After consideration it was recommended and approved that no changes be made to the max dosing of this medication.

6. Old Business:
 - Review of bioequivalence ratings: Documents detailing this information were distributed, reviewed and discussed in detail. A copy will be emailed to each PMAC member. No further actions recommended.
 - Review of generic alternatives to stimulant medications: Documents detailing this information were distributed, reviewed and discussed in detail. Noted this may be a useful reference tool. A copy will be emailed to each PMAC member. Additionally CMCU staff may use this information as a reference tool. No further actions recommended.

- Continuing education outreach to providers: Jill Wood sent an email asking for areas of interest. She will continue with this effort. She suggested having webinars if funding is available. Usual cost is <\$1,000.00. Usual attendance 30-100. This will be discussed further at the Executive Committee meeting. A recommendation was made to do a “Grand Rounds” at Solnit as a method of education outreach. A suggestion was made to have Dr. Amy Veivia (Pharmacist) present on a medication related topic such as “New Drugs in the Pipeline”. The date would be the third Wednesday of November or December 2018. This idea was endorsed by the PMAC.

- Treating substance abuse disorders in children and adolescents: One article was found relating to this subject matter but contained no new actionable information.

7. New Business: None

8. Other as time allows.

Lupron use was briefly discussed as it related to retarding the maturing process of autistic children. No actions recommend.

9. Dr. Nikolov adjourned the meeting at 2:15PM.

Respectfully submitted by: David S. Aresco, Pharmacist